Efter 6 måneder var andelen af overlevende patienter signifikant større i TMZ- gruppen (60%) sammenlignet med procarbazin - gruppen (44%) (chi- square p = 0, 019).
At 6 months, the fraction of surviving patients was significantly higher in the TMZ arm (60%) compared with the procarbazine arm (44%) (chi-square p = 0.019).